about
An assessment of health status among medical research volunteers who served in the Project Whitecoat program at Fort Detrick, MarylandProtective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccinationAdvances in development of countermeasures for potential biothreat agents.Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine.Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.Human transcriptome response to immunization with live-attenuated Venezuelan equine encephalitis virus vaccine (TC-83): Analysis of whole blood.Transcriptional profiling of recall responses to Francisella live vaccine strain.Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study.Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans.Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea.Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.Povidone Iodine Ointment Application to the Vaccination Site Does Not Alter Immunoglobulin G Antibody Response to Smallpox Vaccine.Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome.Immunologic interference from sequential administration of live attenuated alphavirus vaccines.Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccineAnthrax vaccine: increasing intervals between the first two doses enhances antibody response in humansAluminum-containing vaccine associated adverse events: role of route of administration and genderManagement guidelines for laboratory exposures to agents of bioterrorismLong-term health effects of repeated exposure to multiple vaccinesDominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccinationImmune interference after sequential alphavirus vaccine vaccinationsRudolf Hess - The Doppelgänger conspiracy theory disproved
P50
Q28244958-AFB39F2C-3684-4826-92BB-D45650C41EE3Q28384322-0F9BBE33-3473-49B1-A43E-6A62F2B95C8EQ33743444-C3F5B6A2-980B-43EE-A76D-4300FA39858CQ36003482-BE199214-4090-4277-AF15-C8592D3D45B1Q36111585-BD94C993-B5B5-416F-9864-4A9CB743532FQ36403842-22777693-7433-4FD9-919C-0161B276686EQ36514844-D4DD1C2C-2793-4461-A24A-32D43001BBDCQ37619144-89C36DFB-D6AC-4D25-8CE8-B6F5C895EF0BQ39266569-05D1E884-9284-489A-A320-860DDC968B6FQ39778317-9D645D04-7547-472E-8293-07CFD40DCD2AQ40124756-F7C2FAF7-E11B-49AA-B9CD-00A68CCC399DQ40405892-65EA78A2-7EAB-45DB-B9D9-B8276DEF90A4Q40632227-3C41B02F-711E-4C45-9B6B-A3BA93E350A3Q40663422-954C4DDD-D8ED-46AD-9AA3-90529821A01CQ41268640-FE783A1F-BE87-4FE5-8223-949870F4E63DQ42214858-A37AD00C-EA1B-4F12-8266-CB8DD4A3677CQ42248129-90041186-C8D1-44A6-BF9C-62E51FAD14C0Q43462537-7FCAAAB0-9526-4335-A0CF-7D425E431A0EQ44851631-99A855FF-1F2E-4506-99A3-17291C505DC6Q46960051-B5D61F81-25AD-4FC7-B578-36471DE758F8Q71356875-CC3C11B7-06EC-4AC8-85B8-59077470A08DQ74128249-5BD3C71F-9E7E-4161-84E3-80AB6D1E5F61Q74622684-C6CC6C0A-10B2-4BED-B07C-79D613DD4891Q80427533-8C61D9D8-AE3C-4AB1-8733-570A11FD432EQ80973115-23E33205-CE35-4549-BB8C-359BD720751EQ83288682-819AA634-1848-424C-A5F4-7839E691E3A9Q84168670-C628ECBF-84FA-423C-BE6E-CD36B439EC15Q91238441-58F3BF07-D1B3-42B1-82B2-81EA72F7FB68
P50
description
researcher
@en
wetenschapper
@nl
name
P R Pittman
@en
P R Pittman
@nl
type
label
P R Pittman
@en
P R Pittman
@nl
prefLabel
P R Pittman
@en
P R Pittman
@nl
P106
P31
P496
0000-0003-1787-759X